I think this is great news!
http://www.mstrust.org.uk/news/article.jsp?id=5914
Alemtuzumab has moved closer to being licensed following a decision by a committee of the European drug regulator.
Alemtuzumab is a disease modifying treatment for people with relapsing remitting MS. In clinical trials, people taking alemtuzumab had about half the number of relapses as those taking interferon beta 1a (Rebif). Alemtuzumab is taken as a course of intravenous (iv) infusions over five consecutive days at the start of treatment and again, over three days, one year later. In most people, no further treatment is necessary.
The Committee for Medicinal Products for Human Use (CHMP) assesses drugs for quality, safety and efficacy and recommends which should be licensed by the European Medicines Agency (EMA). CHMP has recommended approval of alemtuzumab for the treatment of adults with active relapsing remitting MS, defined by clinical or MRI features. Unless the manufacturer asks CHMP to reassess their decision, the final decision on a licence will be issued in the next three months.
Alemtuzumab is a disease modifying treatment for people with relapsing remitting MS. In clinical trials, people taking alemtuzumab had about half the number of relapses as those taking interferon beta 1a (Rebif). Alemtuzumab is taken as a course of intravenous (iv) infusions over five consecutive days at the start of treatment and again, over three days, one year later. In most people, no further treatment is necessary.
The Committee for Medicinal Products for Human Use (CHMP) assesses drugs for quality, safety and efficacy and recommends which should be licensed by the European Medicines Agency (EMA). CHMP has recommended approval of alemtuzumab for the treatment of adults with active relapsing remitting MS, defined by clinical or MRI features. Unless the manufacturer asks CHMP to reassess their decision, the final decision on a licence will be issued in the next three months.